Back | Next |
home / stock / lexx / lexx message board
Subject | By | Source | When |
---|---|---|---|
.76 pre market | PotsandPans420 | investorshub | 05/09/2023 10:46:19 AM |
Bunka is running the biggest con of this | all4weed | investorshub | 05/09/2023 3:15:39 AM |
announced the pricing of its public offering of | PotsandPans420 | investorshub | 05/09/2023 1:44:44 AM |
Ted Ohashi-Let's Toke Business | Shawking | investorshub | 05/08/2023 8:12:17 PM |
he has to answer questions honestly for a | harlem111 | investorshub | 05/08/2023 7:09:59 PM |
I did vote on everything against Bunka and | all4weed | investorshub | 05/08/2023 6:33:26 PM |
Surprised Bunka cannot get a secure loan on | Tech99989 | investorshub | 05/08/2023 5:54:34 PM |
definitely a Hail Mary play for me....but getting | harlem111 | investorshub | 05/08/2023 4:52:47 PM |
$LEXX Price now last up | all4weed | investorshub | 05/08/2023 4:25:25 PM |
Preyhoping this week will be a better | Tech99989 | investorshub | 05/08/2023 2:50:04 PM |
FYI. Lexaria's Human Clinical Nicotine Study Completes Dosing | harlem111 | investorshub | 05/08/2023 1:12:09 PM |
good read | Shawking | investorshub | 05/08/2023 5:01:43 AM |
MomentumIts trading last trade up | Shawking | investorshub | 05/07/2023 3:21:27 AM |
$LEXX The now | Tech99989 | investorshub | 05/05/2023 9:44:53 PM |
should we be shorting? | adam69 | investorshub | 05/05/2023 7:06:34 PM |
Bunko had a guy from Maxim group from | harlem111 | investorshub | 05/04/2023 8:11:35 PM |
I am done - but will not sell | harlem111 | investorshub | 05/04/2023 8:06:20 PM |
Bunka is basically stealing from shareholders. By repricing | Tech99989 | investorshub | 05/04/2023 8:00:45 PM |
Pretty much. It's going to be a long | Shawking | investorshub | 05/04/2023 5:02:21 PM |
So we're done? | adam69 | investorshub | 05/04/2023 4:38:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
3.3%Change Percent:
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...